Zydus and Apollo Hospitals sign MoU to launch MCD test in India

Zydus Lifesciences has entered an MoU with Apollo Hospitals to expand access to the Shield multi-cancer detection (MCD) test in India. The agreement is part of Zydus’s exclusive arrangement with Guardant Health to introduce the Shield test in the Indian market. The test is designed for individuals aged 45 and above who are at average risk for cancer. Credit: tilialucida / Shutterstock.com. Zydus Lifesciences has entered a memorandum of understanding (MoU) with Apollo Hospitals to expand access to the Shield multi-cancer detection (MCD) test in India. Developed by Guardant Health, the test is a methylation-based blood test intended to detect…

Source: Medical Device Network